Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 1/20 | 0.53 |
| ▸ | RET | P07949 | 1/20 | 0.53 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.53 |
| ▸ | FLT3 | P36888 | 1/20 | 0.53 |
| ▸ | CNR1 | P21554 | 16/20 | 0.51 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.48 |
| ▸ | RAF1 | P04049 | 1/20 | 0.47 |
| ▸ | CNR2 | P34972 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18039602 | 0.93 | GRM2 (0.52) | CSF1RRETPDGFRBFLT3CNR1 | |
| SCHEMBL18039678 | 0.92 | CSF1R (0.49) | CSF1RRETPDGFRBFLT3CNR1 | |
| SCHEMBL18054770 | 0.91 | RAF1 (0.50) | CSF1RRETPDGFRBFLT3CNR1 | |
| SCHEMBL18039682 | 0.90 | FLT3 (0.57) | CSF1RRETPDGFRBFLT3GRM2 | |
| SCHEMBL18054776 | 0.90 | CSF1R (0.57) | CSF1RRETPDGFRBFLT3CNR1 | |
| SCHEMBL18039623 | 0.90 | GRM2 (0.48) | CSF1RRETPDGFRBFLT3GRM2 | |
| SCHEMBL19837784 | 0.87 | GRM2 (0.46) | CSF1RRETPDGFRBFLT3CNR1 | |
| SCHEMBL18039611 | 0.87 | RAF1 (0.64) | CSF1RRETPDGFRBFLT3RAF1 | |
| SCHEMBL18054777 | 0.85 | CSF1R (0.57) | CSF1RRETPDGFRBFLT3GRM2 | |
| SCHEMBL18039578 | 0.84 | CSF1R (0.58) | CSF1RRETPDGFRBFLT3CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10174047-B2 | Thienodiazepine derivatives or pharmaceutically acceptable salts thereof, and pharmaceutical composition including the same as an active ingredient | INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY ERICA CAMPUS (KR) | 2019-01-08 | — | — | US | claimed |
| US-20180037589-A1 | THIENODIAZEPINE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT | INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY ERICA CAMPUS (KR) | 2018-02-08 | — | — | US | claimed |
| US-10174047-B2 | Thienodiazepine derivatives or pharmaceutically acceptable salts thereof, and pharmaceutical composition including the same as an active ingredient | INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY ERICA CAMPUS (KR) | 2019-01-08 | — | — | US | disclosed |
| US-10174047-B2 | Thienodiazepine derivatives or pharmaceutically acceptable salts thereof, and pharmaceutical composition including the same as an active ingredient | INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY ERICA CAMPUS (KR) | 2019-01-08 | — | — | US | disclosed |
| US-20180037589-A1 | THIENODIAZEPINE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT | INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY ERICA CAMPUS (KR) | 2018-02-08 | — | — | US | disclosed |
| US-20180037589-A1 | THIENODIAZEPINE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT | INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY ERICA CAMPUS (KR) | 2018-02-08 | — | — | US | disclosed |
| US-20180037589-A1 | THIENODIAZEPINE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT | INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY ERICA CAMPUS (KR) | 2018-02-08 | — | — | US | disclosed |
| WO-2016137060-A1 | THIENODIAZEPINE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT | 한양대학교 에리카산학협력단 | 2016-09-01 | — | — | WO | disclosed |
| WO-2016137060-A1 | THIENODIAZEPINE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT | 한양대학교 에리카산학협력단 | 2016-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180037589-A1 | THIENODIAZEPINE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT | RET, PDGFRB, FLT3 | CSF1R 97/4885RET 1/4885PDGFRB 2/4885 |
| US-10174047-B2 | Thienodiazepine derivatives or pharmaceutically acceptable salts thereof, and pharmaceutical composition including the same as an active ingredient | PDGFRB, RET, PDGFRA | CSF1R 78/4885RET 2/4885PDGFRB 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.